IMIQUIMOD (imiquimod) by Design Pharmaceuticals is interferon inducers [moa]. First approved in 2010.
Drug data last refreshed 20h ago
Interferon Inducers
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinoma
Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma
Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)
Safety and Efficacy of GX-188E Administered Via EP Plus GX-I7 or Imiquimod.
Topical Challenge With Omiganan and Imiquimod in Healthy Volunteers
Worked on IMIQUIMOD at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.